Location
Moultrie, GA
Start Date
17-4-2026 12:00 PM
End Date
17-4-2026 1:00 PM
Description
Introduction:
Benign Prostatic Hyperplasia is one of the most prevalent urologic conditions affecting aging men and is characterized by non-malignant proliferation of stromal and epithelial components within the prostate gland. The condition commonly produces lower urinary tract symptoms including urinary frequency, urgency, nocturia, and incomplete bladder emptying. Although BPH is generally viewed as a localized disorder of the lower urinary tract, emerging literature suggests that it may have broader systemic implications. In particular, several studies indicate that BPH and its associated symptoms may indirectly contribute to increased cardiovascular morbidity and mortality. Understanding the potential links between BPH and adverse cardiovascular outcomes is important for improving clinical management in elderly patients who already possess elevated baseline cardiovascular risk. This literature review evaluates proposed mechanisms linking BPH and its management to cardiovascular complications and increased risk of Cardiac Arrest.
Methods: Peer-reviewed literature examining systemic consequences of BPH was reviewed to identify pathways that may contribute to cardiovascular risk. Particular attention was given to three potential mechanisms: pharmacologic treatment effects, metabolic complications arising from urinary obstruction, and sleep disturbances related to lower urinary tract symptoms.
Results: Evidence suggests that multiple pathways may link BPH with cardiovascular complications. Pharmacologic management of BPH frequently involves the use of α-adrenergic blockers to relieve bladder outlet obstruction and improve urinary flow. However, some studies report that these medications may be associated with an increased risk of developing Heart Failure, which is a known contributor to cardiac arrest and other severe cardiovascular events. In addition to medication-related effects, progressive prostatic enlargement can lead to chronic urinary retention and obstructive uropathy. Persistent urinary obstruction may impair renal function and lead to metabolic abnormalities such as Uremia and electrolyte disturbances including Hyperkalemia. Elevated potassium levels disrupt myocardial electrical conduction and may precipitate life-threatening cardiac arrhythmias. Furthermore, lower urinary tract symptoms such as nocturia frequently disrupt normal sleep patterns. Chronic sleep fragmentation may result in persistent Insomnia, which has been associated with increased cardiovascular mortality through mechanisms including autonomic nervous system dysregulation, activation of the hypothalamic–pituitary–adrenal axis, systemic inflammation, and adverse blood pressure regulation.
Discussion: Current literature suggests that BPH may contribute indirectly to cardiovascular mortality through interconnected mechanisms involving treatment-related cardiac effects, metabolic complications of urinary obstruction, and chronic sleep disturbances. Although BPH itself is rarely considered a direct cause of death, these pathways demonstrate how a chronic urologic condition may influence systemic health and increase susceptibility to severe cardiovascular events. Greater recognition of these associations may improve monitoring and management of patients with BPH, particularly among elderly populations. Further research is needed to clarify the strength of these relationships and to determine treatment strategies that effectively manage BPH symptoms while minimizing cardiovascular risk.
Embargo Period
5-26-2026
Included in
Literature Review: Relationship Between Benign Prostatic Hyperplasia and Cardiovascular Mortality
Moultrie, GA
Introduction:
Benign Prostatic Hyperplasia is one of the most prevalent urologic conditions affecting aging men and is characterized by non-malignant proliferation of stromal and epithelial components within the prostate gland. The condition commonly produces lower urinary tract symptoms including urinary frequency, urgency, nocturia, and incomplete bladder emptying. Although BPH is generally viewed as a localized disorder of the lower urinary tract, emerging literature suggests that it may have broader systemic implications. In particular, several studies indicate that BPH and its associated symptoms may indirectly contribute to increased cardiovascular morbidity and mortality. Understanding the potential links between BPH and adverse cardiovascular outcomes is important for improving clinical management in elderly patients who already possess elevated baseline cardiovascular risk. This literature review evaluates proposed mechanisms linking BPH and its management to cardiovascular complications and increased risk of Cardiac Arrest.
Methods: Peer-reviewed literature examining systemic consequences of BPH was reviewed to identify pathways that may contribute to cardiovascular risk. Particular attention was given to three potential mechanisms: pharmacologic treatment effects, metabolic complications arising from urinary obstruction, and sleep disturbances related to lower urinary tract symptoms.
Results: Evidence suggests that multiple pathways may link BPH with cardiovascular complications. Pharmacologic management of BPH frequently involves the use of α-adrenergic blockers to relieve bladder outlet obstruction and improve urinary flow. However, some studies report that these medications may be associated with an increased risk of developing Heart Failure, which is a known contributor to cardiac arrest and other severe cardiovascular events. In addition to medication-related effects, progressive prostatic enlargement can lead to chronic urinary retention and obstructive uropathy. Persistent urinary obstruction may impair renal function and lead to metabolic abnormalities such as Uremia and electrolyte disturbances including Hyperkalemia. Elevated potassium levels disrupt myocardial electrical conduction and may precipitate life-threatening cardiac arrhythmias. Furthermore, lower urinary tract symptoms such as nocturia frequently disrupt normal sleep patterns. Chronic sleep fragmentation may result in persistent Insomnia, which has been associated with increased cardiovascular mortality through mechanisms including autonomic nervous system dysregulation, activation of the hypothalamic–pituitary–adrenal axis, systemic inflammation, and adverse blood pressure regulation.
Discussion: Current literature suggests that BPH may contribute indirectly to cardiovascular mortality through interconnected mechanisms involving treatment-related cardiac effects, metabolic complications of urinary obstruction, and chronic sleep disturbances. Although BPH itself is rarely considered a direct cause of death, these pathways demonstrate how a chronic urologic condition may influence systemic health and increase susceptibility to severe cardiovascular events. Greater recognition of these associations may improve monitoring and management of patients with BPH, particularly among elderly populations. Further research is needed to clarify the strength of these relationships and to determine treatment strategies that effectively manage BPH symptoms while minimizing cardiovascular risk.